Regulus Therapeutics (NASDAQ:RGLS) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of Regulus Therapeutics (NASDAQ:RGLSGet Rating) in a report published on Monday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.

Other research analysts have also recently issued reports about the company. Canaccord Genuity Group initiated coverage on Regulus Therapeutics in a research note on Tuesday, November 8th. They set a buy rating and a $9.00 price target on the stock. Canaccord Genuity Group initiated coverage on Regulus Therapeutics in a research note on Monday, November 7th. They set a buy rating and a $9.00 price target on the stock. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of Moderate Buy and a consensus target price of $12.67.

Regulus Therapeutics Stock Performance

RGLS opened at $1.72 on Monday. Regulus Therapeutics has a one year low of $1.33 and a one year high of $4.20. The stock has a market capitalization of $25.09 million, a PE ratio of -0.78 and a beta of 1.63. The business’s 50 day moving average price is $1.69 and its 200 day moving average price is $2.07.

Institutional Trading of Regulus Therapeutics

Several hedge funds have recently modified their holdings of RGLS. Vanguard Group Inc. raised its stake in shares of Regulus Therapeutics by 21.4% in the first quarter. Vanguard Group Inc. now owns 3,678,334 shares of the biopharmaceutical company’s stock valued at $1,096,000 after acquiring an additional 648,121 shares in the last quarter. Federated Hermes Inc. purchased a new position in Regulus Therapeutics in the first quarter valued at $8,656,000. Northern Trust Corp increased its holdings in Regulus Therapeutics by 42.9% in the first quarter. Northern Trust Corp now owns 168,172 shares of the biopharmaceutical company’s stock valued at $50,000 after buying an additional 50,518 shares during the last quarter. Renaissance Technologies LLC grew its holdings in shares of Regulus Therapeutics by 498.2% during the first quarter. Renaissance Technologies LLC now owns 133,400 shares of the biopharmaceutical company’s stock worth $40,000 after purchasing an additional 111,100 shares during the last quarter. Finally, Dimensional Fund Advisors LP purchased a new position in shares of Regulus Therapeutics during the third quarter worth about $54,000. 59.60% of the stock is currently owned by institutional investors and hedge funds.

Regulus Therapeutics Company Profile

(Get Rating)

Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease.

Further Reading

Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.